OM
APGE icon

Opaleye Management’s Apogee Therapeutics APGE Stock Holding History

Opaleye Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.8M Hold
390,000
– – 4.69% 6
2026
Q1 		$32.8M Buy
390,000
+1,743
+0.4% +$127K 4.32% 6
2025
Q4 		$29.3M Buy
388,257
+25,000
+7% +$1.57M 3.87% 5
2025
Q3 		$14.4M Buy
+363,257
New +$13.9M 2.04% 12

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Opaleye Management's APGE Position: Q2 2026 in Review

Opaleye Management held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 390,000 shares worth $51.8M. The position accounts for 4.69% of the portfolio, ranked #6.

Opaleye Management first reported a position in APGE in Q3 2025 and has held it in 4 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Opaleye Management held 390,000 shares of Apogee Therapeutics worth $51.8M as of Q2 2026.
  • Opaleye Management left its Apogee Therapeutics share count unchanged in Q2 2026.
  • Apogee Therapeutics made up 4.69% of Opaleye Management's portfolio in Q2 2026, its #6 holding.
  • Opaleye Management first reported a position in Apogee Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.